The original version of this article unfortunately contained mistakes. The percentage value of inhibition induced by MRV3 was incorrect (61.53 % instead of 37.82 %). The correct value now appears below.
Abstract
The compound (−)-MRV3 [(−)-Methyl (1S,2R)-2-[(4-Hydroxy-4-phenylpiperidin-1-yl)-methyl]-1-phenylcyclopropanecarboxylate] has an assessed antagonist sigma 1 (σ 1 ) profile and showed improved σ 1 /σ 2 selectivity with respect to the parent compound (+)-MR200. The σ 1 receptor is reported to play a role in both central sensitization and pain hypersensitivity, which suggests a potential use of σ 1 antagonists for the treatment of persistent pain conditions. The present study was performed to assess the effects of the selective σ 1 antagonist (−)-MRV3, in carrageenan-induced inflammatory hyperalgesia, allodynia and edema. Mechanical allodynia with a series of calibrated von Frey's filaments, thermal hyperalgesia with plantar test and edema evaluation with a plethysmometer were measured. Subcutaneous (s.c.) treatment with (−)-MRV3 (1, 2, 3, 4, 5 mg/kg) dose-dependently reduced allodynia and hyperalgesia induced by intraplantar carageenan. Furthermore, treatment with (−)-MRV3 (3 mg/kg s.c.) also inhibited paw edema with a significant inhibition of 61.53 % 3 h after carrageenan treatment. These results provide a strong basis for the use of σ 1 receptor antagonists in the treatment of inflammatory pain.
The online version of the original article can be found at http:// dx.doi.org/10.1007/s10753-013-9736-6.
